Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I-III biomarker-selected consolidation study in unresectable stage III NSCLC
2021-004149-19Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of alectinib, entrectinib, pralsetinib and durvalumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Feb 2022; status: active.
02
Drugs
alectinibentrectinibpralsetinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004149-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004149-19.